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Mahamrutyunjaya rasa (MHR), an Ayurvedic formulation, used as cardiotonic, contains potentially toxic compounds like
aconitine, which are detoxiﬁed during preparation using traditional methods. Comparative toxicological evaluation of laboratory
prepared formulation (F1) and two marketed formulations (F2 and F3) were performed based on their eﬀects on viability of H9c2
cells and after single oral dose administration in mice. Cardioprotective eﬀect of formulations at 25 and 50mg/kg doses were
studied in isoproterenol- (ISO-) induced myocardial infarcted rats. F1 and F2 did not aﬀect the cell viability, while F3 decreased
the cell viability in concentration and time-dependent manner. Rats administered with ISO showed signiﬁcant increase in the
serum levels of glutamate oxaloacetate transaminase, alkaline phosphotase, creatinine kinase isoenzymes, lactate dehydrogenase,
and uric acid, while F1 and F2 treatment showed signiﬁcant reduction in the same. F3 showed further increase in the serum
levels of enzymes and uric acid in ISO-challenged rats. High pressure liquid chromatographic analysis of formulations showed
higher concentration of aconitine in F3. Study shows that F1 and F2 possess cardioprotective property with higher safety, while
formulation F3 cannot be used as cardioprotective due to its cytotoxic eﬀects. Thus, proper quality assessment methods are
required during preparation of traditional formulations.
1.Introduction
Today, herbal remedies are back into prominence because
the eﬃcacy of conventional medicines such as antibiotics,
which once had near universal eﬀectiveness against serious
infections, is on the wane. In Ayurveda (traditional Indian
medicine) about 2,000 plant species are considered to have
medicinal value, while the Chinese Pharmacopoeia lists over
5,700 traditional medicines, most of which are of plant
origin [1].
Although modern drugs are eﬀective in the symptomatic
control of cardiovascular disease, their use is often associated
with a number of undesirable eﬀects [2]. Various ayurvedic
formulations have been found to be clinically useful remedy
in a number of disorders with advantages like better accep-
tancebythepatientandlesscost[3,4].However,theclaimed
pharmacological activities of many of these formulations
have not been proven nor refuted by controlled studies.
Present studies on ayurvedic cardiotonic formulations are
of important considerations, since cardiovascular remedies
are usually taken for long periods of time. MHR is a kind
of compound herbo-mineral formulation often used to treat
cardiac disorders [5]. The medicine comprises four kinds of
herbs: Aconitum ferox, Solanum indicum, Piper nigrum and
Piper longum. Ayurvedic literature [6] records the formula
of MHR tablet as 1 part each of powdered processed
Aconitum ferox, Solanum indicum, Piper nigrum, and Piper
longum, sieved and then mixed with 1 part each of puriﬁed
sulphur and puriﬁed sodium metaborate. To this mixture
2 parts of puriﬁed cinnabar (HgS) were added and mixed
uniformly. In this complex formulation, the mixtures of
plant constituents act synergistically to increase the activity
and also at times counteract the toxic eﬀect of compounds
[7]. Aconite root contains various toxic diester-diterpene
alkaloids like Aconitine, which is known for its cardiotonic
[8], anti-inﬂammatory, and analgesic eﬀects[9]. The LD50 of2 Evidence-Based Complementary and Alternative Medicine
Aconitine in mice is 1.8mg/kg. The puriﬁcation of Aconitum
roots is done by soaking the roots in cow urine for 48h
followed by washing them with cow milk. The roots have
to be then washed with water and dried [10]. Solanum
roots also contain toxic glycoalkaloids α-Solanine with LD50
of 0.68mmol/kg in mice [11]. The heavy metal content of
this formulation can also present serious risk to human
health [12]. Shodhana (puriﬁcation), a traditional ayurvedic
treatment was used to decrease the toxicity and increase
the bioactivity of the active ingredients in the preparation
of MHR [13]. If this puriﬁcation is not performed as per
the standard text, undesirable eﬀects of formulation may be
observed after administration in humans [14]. The toxico-
logical and pharmacological properties of MHR have not
been subjected to any scientiﬁcally controlled investigations
so far. Thus, it becomes important for the physicians and
producers to be aware of the safety and eﬃcacy of MHR.
The present investigations have therefore been designed
to explore the toxicological and pharmacological eﬀects of
MHR to substantiate the claims made in Ayurveda as well
as by traditional healers and provide a platform to prove the
safety of such formulations.
In this study we investigated the cardioprotective
action of various MHR formulations in experimentally
induced cardiac damage. We used Isoproterenol (ISO) (1-
(3 ,4 -dihydroxyphenyl)-2-isopropylaminoethanol hydro-
chloride), a nonselective β-adrenergic agonist, which causes
infarct-like necrosis of the heart muscle with subsequent
leakage of cardiac enzymes in blood leading to cardiac
dysfunction in rats [15–17]. Cardioprotective action of
MHR was studied in ISO-challenged rats. We further studied
cytotoxicity of MHR formulation using rat embryonic
cardiac cell line (H9c2). Chromatographic analysis of
selected MHR formulations was performed in order to
validate the puriﬁcation process of one of the ingredients
used during its preparation.
2. Experimental
The present study was performed on biological and toxi-
cological aspects of MHR. Three formulations (F1, F2, and
F3) were selected. F1 was prepared in laboratory as reported
in the traditional text; F2 was procured from Baidyanath,
(Nagpur, India), while formulation F3 was purchased from
Pune Rasashala, (Pune, India).
2.1. Chemicals and Reagents. Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) and fetal calf serum (FCS) were obtained
from GIBCO, Invitrogen Corporation, Carlsbad, California.
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bro-
mide (MTT), streptomycin, isoproterenol, and trypsin were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
HPLC grade acetonitrile and methanol and analytical grade
Potassium dihydrogen phosphate (KH2PO4), triethylamine,
and 85% ortho-phosphoric acid (H3PO4), were purchased
from (Qualigens, Mumbai). Triple distilled water was used
throughout the study. Serum GOT and ALK-P and uric acid
detection kits were purchased from (Sigma Diagnostic Kit,
Sigma-Aldrich Corp., St. Louis, MO), while LDH detection
kit from (Teco Diagnostics, Anaheim, CA, USA). All other
chemicals used were of the highest grade available.
2.2.SamplePreparation. Theformulationsintabletform(F2
and F3) were purchased from the local market. The tablets
were powdered and suspended in water using 1% tween 80
for the in vivo studies. Alkaloid fractions of the formulations
(F1, F2, and F3) were prepared as per the reported method
[18] and fractions were dried under high vacuum for several
hours to remove any traces of solvents used during their
processing. The dried fractions were dissolved in dimethyl
sulfoxide (DMSO) in aseptic conditions and ﬁltered through
0.25μm syringe ﬁlter and then used for in vitro studies.
The ﬁnal concentration of DMSO was not more than 0.2%
during the experiments.
2.3. Animals. Female Balb/c mice weighing between 20–
25g and male albino rats of Wistar strain weighing 250
to 280g (Cadila Pharmaceuticals, Ahmedabad, India) were
housed for at least 4 days before being used in a room with
controlled temperature (23±1◦C), humidity (50±10%) and
light (6:00A.M. to 6:00P.M.). Food and water were made
available continuously. Animal care and use forexperimental
procedures were approved by the Institutional animal care
and use committee. All anesthetic and procedures were in
compliance with the guidelines established by the Animal
Care Committee (Pharmacy department/M. S. University,
Baroda/404/01/1/CPCSEA).
2.4. Cell Culture and Treatment. The H9c2 cell line derived
fromembryonicrathearttissuewaspurchasedfromAmerica
Tissue Type Collection (Manassas, VA; catalog # CRL-1446).
Cells were cultured in DMEM supplemented with 10%
FCS, 100U/mL of penicillin, and 100μg/mL of streptomycin
in 75cm2 tissue culture ﬂasks at 37◦C in a humidiﬁed
atmosphere of 5% CO2. Alkaloidal fractions of formulations
dissolved in DMSO were suspended in sterile DMEM for in
vitro assay.
2.5. Single Dose Toxicity of Formulations in Mice. Toxicity
study with single oral doses of formulations was carried out
as per the OECD guidelines using mice [19]. Mice were
administered orally with single dose of 2000, 1550, 550,
175, 55mg/kg of formulations and observed for any signs of
toxicity and mortality. Histopathological examination of the
visceral organs like heart, kidney, and liver was done in order
to observe the toxic eﬀects of formulations [20].
2.6. Cell Viability Study of Formulations in Rat Embryonic
Cardiac Cells. The viability of H9c2 cells after treatment
with alkaloidal fractions of formulations F1, F2, and F3
was assayed by the reduction of MTT to formazan as
described previously [21]. The cells (5 × 103)w e r ec u l t u r e d
in 96—well microtiter plates, and left overnight in an
incubator at 37◦Cw i t h5 %C O 2 before being exposed to
diﬀerent concentrations of formulations. Cells were treated
with diﬀerent concentrations (2, 5, 10, 20, 50, 100, and
200μg/mL) of F1, F2, and F3 for 12, 24, and 48h and their
viability was determined using 10μLo f5 m MM T Tw i t hEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Microscopic images of mice heart, kidney, and liver illustrating eﬀect of single oral dose administration of formulation F1, F2,
and F3 (Staining: Hematoxylin and Eosin). Microscopic images of mice heart from (a) F1, (b) F2, (c) F3 groups; images of mice kidney from
(d) F1, (e) F2, and (f) F3 images of mice liver from (g) F1, (h) F2, and (i) F3 groups. Solid arrow indicates the normal; and unﬁlled arrow
indicates the aﬀected/infracted/injured area of kidney/heart//liver.
additional incubation for 4h. Thereafter, the medium was
removed, the formazan crystals were dissolved in 100μL
of DMSO and the absorbance was measured at 570nm
using microplate reader (Molecular Devices, Spectra MAX
250). The data of the survival curves were expressed as the
percentage of untreated controls [22].
2.7. Protective Eﬀect of Formulations against ISO-Induced
Myocardial Infarction (MI) in Rats. Cardioprotective eﬀect
of formulations was studied in ISO-induced myocardial
infarcted rats. Rats were administered with 25 and 50mg/kg
doses of formulations orally for 15 days and at the end of
treatment MI was induced by injecting 25mg/kg s.c. dose
of ISO twice at the interval of 24h. The protective eﬀect
of formulations was evaluated by comparing the results
with vehicle-treated rats injected with ISO. The experimental
design for the study has been shown in Table 1. At the end
of experiment, rats were sacriﬁced under ether anesthesia,
blood was collected through carotid artery, and serum was
separated. Serum levels of cardiac marker enzymes like
lactate dehydrogenase (LDH), creatine kinase isoenzymes
(CK-MB), glutamate-oxaloacetate transaminase (GOT), and
alkaline phosphatase (ALK-P) along with uric acid was
determined in order to evaluate the cardiac injury. Serum
ALK-P, GOT were determined using commercial kits (Sigma
Diagnostic Kit, Sigma-Aldrich Corp., St. Louis, MO) [23,
24], while serum levels of uric acid were determined by
spectrophotometric assay (Sigma, St. Louis, MO) [25]. CK-
MB activity was determined with a colorimetric method
using a CK-MB immunoinhibition kit (Euro Diagnostic
System Pvt. Ltd, Chennai, India), based on the principle
of immunoinhibition of one of the subunits (CK-M and
CK-B) of the enzyme creatine kinase [26]. The enzyme
LDH catalyzes the oxidation of lactate to pyruvate in
the presence of NAD, which is subsequently reduced to
NADH. The rate of NADH formation measured at 340nm
is directly proportional to the serum LDH activity, based
on this principle we measured serum levels of LDH using4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of formulations F1 (a), F2 (b), and F3 (c) on viability of H9c2 cells after 12, 24, and 48h of treatment. Values are expressed
as mean ± SD and are average of three determinations.
commercially available kit (Teco Diagnostics, Anaheim, CA,
USA)[27].Heartwasdissectedout,washedinice-coldsaline
and weighed accurately to determine heart weight/body
weight ratio (HW/BW). Histopathological studies on heart
were carried out in order to assess any changes in cellular
architecture. The body weights of the animals were recorded
throughout the experimental period.
2.8. Chromatographic Analysis. The High Pressure Liquid
chromatography (Shimadzu, Kyoto, Japan) consisted of LC-
20 AT Prominence solvent delivery module (Shimadzu), a
manual injector with a 20μLﬁ x e dl o o p( R h e o d y n e ) ,a n da
SPD-20A Prominence UV-visible detector (Shimadzu) was
used to determine the concentration of active ingredient
in the formulations. The separation was performed on a
C18 column (particle size 5μm; 250mm × 4.6mm ID;
Phenomenex Torrance, USA) preceded by an ODS guard
column (10μm, 10mm × 5mm ID) at an ambient temper-
ature. Chromatographic data were recorded and processed
using a Chromatographic Station CFR Version 2.4.0.193
(Spinchrom Pvt. Ltd., Chennai, India).
2.9. Preparation of Standard Solutions. Standard stock solu-
tions of aconitine (1000μg/mL) were prepared by dissolving
10mgofpureaconitinein10mLmethanol.Furtherdilutions
of standards were made by using aliquots of the stock
and making volume with methanol in order to obtain the
concentration of 10–100μg/mL.
2.10. Preparation of Sample Solutions. Twenty tablets of
all the three formulations were powdered and about 1gm
each of the three formulations was accurately weighed
and extracted in 25mL of 0.1NHCl by sonication for 10
minutes at room temperature. The solutions were further
fractionated with 10 × 3mL ethyl acetate to remove the
nonalkaloid components. The acidic aqueous solutions were
basiﬁed using ammonia to pH 11 and further extracted
with 10 × 3mL chloroform. Chloroform was evaporated
under reduced pressure and residue obtained was dissolved
in methanol by sonication and further dilutions were made
in acetonitrile [28].
2.11. Analytical Conditions. Analysis of aconitine in formula-
tions was isocratic at 1.0mL/min ﬂow rate with ammonium
bicarbonate buﬀer (15mM, pH 7.5 was adjusted using
ammonia): acetonitrile (40:60v/v) as mobile phase. The
analysis was performed at 223nm [29].Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of Formulations on serum levels of (a) CK-MB, (b) LDH, (c) GOT, (d) ALKP, and (e) Uric acid. Group I (1% solution of
tween 80 in water followed by normal saline (2mL/kg, s.c. twice at an interval of 24h)); Group II (1% tween 80 followed by ISO (25mg/kg,
s.c. twice at an interval of 24h)); Group III, VI, IX: (50mg/kg dose of F1, F2, and F3, resp., followed by normal saline (2mL/kg, s.c. twice at
anintervalof24h));GroupIV,VII,X:(administeredorallywith25mg/kgdoseofF1,F2,andF3,respectively,followedbyISO(25mg/kg,s.c.
twice at an interval of 24h)); Group V, VIII, XI (administered orally with 50mg/kg dose of F1, F2, and F3, resp., followed by ISO (25mg/kg,
s.c. twice at an interval of 24h)). #Compared with ISO treated group, ∗Compared with saline treated (control) group.
2.12. Statistical Analysis of Data. Data are presented as Mean
± S.E.M. The signiﬁcance of diﬀerences was estimated by
one-way analysis of variance followed by application of
the Dunnett’s Multiple Comparisons and Tukey-Kramer
Multiple Comparisons test. A P value of less than .05
was considered to be signiﬁcant. The statistical analysis
was processed with GraphPad Prism software Version 5.00
(GraphPad, San Diego, CA, USA).6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀect of formulations F1, F2, and F3 (a) 25mg/kg and
(b) 50mg/kg on Heart weight/body weight ratio (HW/BW). Group
I (1% solution of tween 80 in water followed by normal saline
(2mL/kg, s.c. twice at an interval of 24h)); Group II (1% tween
80 followed by ISO (25 mg/kg, s.c. twice at an interval of 24h));
Group III, VI, IX: (50mg/kg dose of F1, F2, and F3, resp., followed
by normal saline (2mL/kg, s.c. twice at an interval of 24h)); Group
IV, VII, X: (administered orally with 25mg/kg dose of F1, F2, and
F3, resp., followed by ISO (25mg/kg, s.c. twice at an interval of
24h)); Group V, VIII, XI (administered orally with 50mg/kg dose
of F1, F2, and F3, resp., followed by ISO (25mg/kg, s.c. twice at an
interval of 24 h)). ∗Compared with control group.
3. Results
3.1.ToxicityofFormulationsinMiceatSingleDose. Mortality
was observed in mice administered with single oral dose
(2000 and 1550mg/kg) of F1, F2, and F3, while with
550mg/kg dose no mortality was seen. Histopathological
examination of the liver, heart, and kidney from the mice
treated with 550mg/kg dose of F1- and F2-showed normal
cellular architect indicating lack of any toxicity. Liver his-
tology of F-1 and F2-treated mice showed normal cellular
architecture with distinct hepatic cells, sinusoidal spaces,
and prominent central vein (Figures 1(g), 1(h)). Heart
and Kidney sections were free of pathological indications
in F1- and F2-treated groups of mice (Figures 1(a), 1(b),
1(d), 1(e)). Mice treated with 550mg/kg of F3 showed
disturbed liver architect. The hepatic cells appeared as
cloudy swellingwith branchingof centralportal vein. Several
necrotic areas were observed in liver from F3-treated mice
(Figure 1(i)).HistologicalanalysisofKidneyfromF3-treated
mice exhibited disturbed cellular lining, with elongated
tubules. Most of renal tubules were dilated and the epithelial
cells tended to be vacuolated with a foamy appearance
(Figure 1(f)) .H e a r ts e c t i o n sf r o mF 3 - t r e a t e dm i c es h o w e d
infarcted zone with occurrence of oedema and inﬂammatory
cells. Loss of contractile bands with occurrence of necrotic
Table 1: Experimental Design for the determination of protective
eﬀect of formulations against ISO-induced MI in rats.
Groups No. of
Animals Treatment
Group I 6
1% solution of tween 80
in water for 15 days
followed by normal
saline (2mL/kg, s.c.
twice at an interval of
24h)
Group II 6
1% tween 80 for 15 days
followed by ISO
(25mg/kg, s.c. twice at
an interval of 24h)
Group III 6
50mg/kg of F1 for 15
days followed by normal
saline (2mL/kg, s.c.
twice at an interval of
24h);
Group IV 6
25mg/kg of F1 for 15
days followed by ISO
(25mg/kg, s.c. twice at
an interval of 24h)
Group V 6
50mg/kg of F1 for 15
days followed by ISO
(25mg/kg, s.c. twice at
an interval of 24h).
Group VI 6
50mg/kg of F2 for 15
days followed by normal
saline (2mL/kg, s.c.
twice at an interval of
24h);
Group VII 6
25mg/kg of F2 for 15
days followed by ISO
(25mg/kg, s.c. twice at
an interval of 24h)
Group VIII 6
50mg/kg of F2 for 15
days followed by ISO
(25mg/kg, s.c. twice at
an interval of 24h).
Group IX 6
50mg/kg of F3 for 15
days followed by normal
saline (2mL/kg, s.c.
twice at an interval of
24h);
Group X 6
25mg/kg of F3 for 15
days followed by ISO
(25mg/kg, s.c. twice at
an interval of 24h)
Group XI 6
50mg/kg of F3 for 15
days followed by ISO
(25mg/kg, s.c. twice at
an interval of 24h).
areas and displaced nuclei was seen in F3 treated mice.
However, no mortality was observed (Figure 1(c)). Thus,
formulation F3 was found to be toxic. Further toxicological
studies were carried out using rat embryonic cardiac cell line
(H9c2).Evidence-Based Complementary and Alternative Medicine 7
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Figure 5: Microscopic images of rat heart illustrating the eﬀect of formulation F1, F2, and F3 in ISO-induced MI rats (Staining:
Haematoxylin and Eosin). Microscopic images of rat heart from Group I (a), Group II (b), Group III (c), Group IV (d), Group V (e),
Group VI (f), Group VII (g), Group VIII (h), Group IX (i), Group X (j), Group XI (k).
3.2. Study on Eﬀect of Formulation on Viability of H9c2 Cells.
Eﬀect of formulations F1, F2, and F3 on viability of H9c2
cells were studied in comparison to the untreated (control)
cells. Cells incubated with F1 (2 to 200μg/mL) for 12h
showed increased cell viability. Signiﬁcant decrease in cell
viability was observed after 24 and 48h of treatment with
maximum decrease of 47.49% at 24h and 56.34% at 48h
with 200μg/mL concentration (Figure 2(a))
Formulation F2 showed 14.85% decrease in cell viability
at 200μg/mL concentration after 12 h of treatment, while8 Evidence-Based Complementary and Alternative Medicine
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pared in laboratory), F2 (Baidyanath), and F3 (Pune Rasashala).
Retention time of Aconitine ∼8.2mins. (Aconitine content (μgg−1)
in F1-1.06, F2-1.27, and F3-5.10.).
Table 2: Contents of the aconitine in formulations F1, F2, and F3
(n = 3).
Formulation Aconitine Content (μgg−1)
F-1 1.06 ±0.43
F-2 1.27 ±0.42
F-3 5.10 ±0.96
treatment for 24 and 48h decreased cell viability by 65.08%
and 72.66% with 200μg/mL concentrations, respectively,
(Figure 2(b)).
Treatment with formulation F3 decreased cell viability by
34.71,36.08,40.42,31.97,25.35,70.55,and85.55%after12h
of treatment; similarly 24h treatment decreased cell viability
by7.68,6.49,7.94,13.63,22.09,53.84,and94.98%at2,5,10,
20, 50, 100, and 200μg/mL concentrations respectively. Cell
viability was decreased by 7.23, 9.23, 13.01, 24.48, 58.51, and
96.15%with5,10,20,50,100,and200μg/mLconcentrations
respectively, after 48h of treatment (Figure 2(c)).
3.3. Study on Eﬃcacy of F1, F2, and F3 on ISO-Induced MI.
Formulations F1, F2, and F3 were studied for their protective
eﬀect against ISO-induced MI in rats at 25mg/kg and
50mg/kg doses. Group II (vehicle-treated rats injected with
25mg/kg ISO subcutaneously) showed signiﬁcant increase
(P<. 001) in serum levels of CK-MB, LDH, GOT, ALK-
P and uric acid compared to Group I (vehicle-treated rats
injected with normal saline 2mL/kg). Group IV and V
(administered with 25 and 50mg/kg doses of F1), showed
signiﬁcant decrease (P<. 001) in the serum levels of CK-
MB, LDH, GOT, ALK-P and uric acid in a dose dependent
manner compared to Group II (vehicle-treated rats injected
with ISO). Group III (administered with 50mg/kg dose of
F1 alone) showed no change in the levels of these enzymes
compared to Group I.
Group VII and VIII (administered with 25 and 50mg/kg
doses of F2, resp.) showed signiﬁcant decrease (P<. 001)
in ISO-aﬀected levels of CK-MB, LDH, GOT, ALK-P, and
uric acid in a dose-dependent manner compared to Group
II (vehicle-treated group injected with ISO), while Group
VI (administered with 50mg/kg dose of F2 alone) showed
no change in CK-MB, LDH, GOT, ALK-P, and uric acid
compared to Group I.
Group X and XI (administered with 25 and 50mg/kg
doses of F3, resp.) showed signiﬁcantincrease in ISOaﬀected
levels of CK-MB (P<. 01), LDH (P<. 001), GOT (P>. 05),
ALK-P (P<. 001), and uric acid (P>. 05) compared to
Group II. Group IX (administered with 50mg/kg dose of
F3 alone) showed signiﬁcant increase in levels of CK-MB
(P<. 001), LDH (P<. 001), GOT (P<. 001), ALK-P
(P>. 05), and uric acid (P<. 01) compared to Group I.
(Figure 3)
3.4. Heart Weight/Body Weight Ratio of the Groups. Group II
showed signiﬁcant increase (P<. 01) in heart weight/body
weight ratio compared to Group I. Group IV, V, VII, VIII
(F1- and F2-treated groups injected with ISO) showed
signiﬁcant reduction in the ratio compared to Group II.
Heart weight/body weight ratio was signiﬁcantly increased
in F3-treated group compared to Group I and Group II
(Figure 4).
3.5. Histopathological Studies. Cardiac histology of rats from
Group I showed normal myocardial architecture with intact
muscle ﬁbres (Figure 5(a)). Group II showed necrosis of
cardiac muscles with hyalinization of ﬁbres and cellular
inﬁltration(Figure 5(b)).Preinfarctionstagewasobservedin
Group II as seen with occurrence of cellular inﬂammatory
exudate, muscle atrophy, and cytoplasmic vacuolization.
Cardiac muscle ﬁbres were found to be elongated with
occurrence of contractile band lesions. Cardiac histology
of rats from Group III and Group VI were similar to that
of the Group I (Figures 5(c), 5(f)), with minimal damage
and mild swelling of muscle cells and cardiac muscle ﬁbres,
indicating lack of toxicity with formulations F1 and F2.
Groups IV, V, VII, VIII administered with diﬀerent doses
of formulations F1 and F2 showed protection against ISO
induced MI as observed from reduction in necrotic areas
(Figures 5(d), 5(e), 5(g),a n d5(f)). Conspicuous damage of
the myocardium was observed in rats from Group X and XI
(Figure 5(i)). The rats also showed acute myocardial necrosis
consisted of variably sized areas of fragmented myoﬁbers
with inﬂammatory inﬁltrate (Figures 5(j), 5(k)).
Treatment with formulations F-1 and F-2 retains the
normal architecture of the myocardium after ISO challenge,
while F-3 failed to preserve the normal cellular architecture
a n dp r o v e dt ob ec a r d i o t o x i c .
3.6. High-Performance Liquid Chromatography Analysis. The
amount of aconitine was estimated in formulations F1,
F2, and F3. The retention time of aconitine was found
to be 8.2 minutes. The peak areas and peak heights were
recorded. Aconitine content of formulation F3 was much
higher compared to F1 and F2. The data (Figure 6 and
Table 2) showed the correlation between the toxicity proﬁle
and concentration of the aconitine, indicating improper
method of preparation.
4. Discussion
Mahamrutyunjaya rasa (MHR) is a cardiotonic herbo-
mineralformulationcontaininglargenumberofingredients,
which need to be puriﬁed and detoxiﬁed by ShodhanaEvidence-Based Complementary and Alternative Medicine 9
Laboratory prepared
formulations
Biological evaluation of ayurvedic
formulation mahamrutyunjaya rasa
Toxicological study of F1,
F2,F3 as per OECD
guidelines inmice
Cell viability assay of F1,F2,
F3 on rat embryonic cardiac
cells (200 μg/mL)
Cardioprotective eﬀect of F1,
F2,F3 in rats with respect to
serum levels of CK-MB,LDH,
ALK-P,GOT and Uric acid
HPLC assay of aconitine
in formulations F1,F2 and F3
Non toxic at 550 mg/kg Non toxic at 550 mg/kg
Increase in 12 hrs
Decreased 47.49% in 24 hrs
Decreased 56.34%in 48 hrs
No mortality, but minor
changes in cellular
architecture of heart,
kidney and liver
Decreased 14.85%in 12 hrs
Decreased 65.08% in 24 hrs
Decreased 72.66%in 48 hrs
Decreased 85.55%in 12 hrs
Decreased 94.98% in 24 hrs
Decreased 96.15%in 48 hrs
Showed signiﬁcant
protection against ISO
induced cardiac damage
Showed signiﬁcant
protection against ISO
induced cardiac damage
Showed signiﬁcant
cardiac damage in F3
treated rats itself
1.06 ± 0.43 μgg−1 1.27 ± 0.42 μgg−1 5.1 ± 0.96 μgg−1
Indicates standard
method of preparation
of formulation
Indicates improper
method of preparation
of formulation
Marketed formulations
F1 F2 F3
Figure 7: Schematic Representation of the study performed for the biological evaluation of Mahamrutyunjaya rasa.
before being incorporated into the formulation [30]. These
ingredients may prove toxic if not processed according to
the standard text. Due to lack of investigations on the tox-
icity proﬁle and evidences supporting the pharmacological
activity, we performed various in vitro and in vivo studies on
MHRtovalidateitstraditionalmethodofpreparationandto
provide an important standardization tools for its stringent
control.
Our studies indicate higher safety margin for formula-
tions F1 (prepared in the laboratory as per the standard
text) and F2 (procured from Baidyanath) as observed from
results of cell viability assay and acute toxicity study in
mice. Formulation F3 showed signiﬁcant toxicity in in vitro
and in vivo studies. The viability of H9c2 cells decreased
signiﬁcantly even with lower concentrations of F3 and its
acute administration in mice signiﬁcantly aﬀected the nor-
mal cardiac cellular architecture indicating its toxic nature.
In order to evaluate the cardioprotective eﬀect of for-
mulations F1, F2, and F3, in vivo studies were carried
out using ISO-induced MI in rats. Myocardial necrosis
induced by ISO is probably due to a primary act on
the sarcolemmal membrane, followed by stimulation of
adenylate cyclase, activation of Ca2+ and Na+ channels,
exaggerated Ca2+ inﬂow, excess of excitation-contraction
coupling mechanism, energy consumption, and cellular
death [16]. Increased serum levels of CK-MB, LDH, ALK-
P, GOT and uric acid are the diagnostic indicators of ISO-
induced MI. An increase in the activity of these enzymes in
serum is due to their leakage from myocytes as a result of
necrosis induced by ISO. Increase in serum uric acid could
be due to excessive degradation of purine nucleotides and
proteolysis. Cardioprotective eﬀects of formulations were
assessedbyanalyzingthelevelsofserummarkerenzymeslike
GOT, ALK-P, CK-MB, LDH, and uric acid.
In the above study, ISO treatment in vehicle treated rats
resulted in a marked elevation of CK-MB level, while F1
and F2 treatment prevented the maximum increase of CK-
MB during the peak infarction in the tissues. Moreover, the
activities of other cardio-speciﬁc enzyme-like LDH, GOT,
and ALK-P in the serum were also found to be reduced with
F1 and F2 treatment in MI rats.
The cardioprotective action of MHR may be due to
a number of components present in the formulation.
Aconitum roots containing the diterpenoid alkaloids-like
aconitine can be one of the ingredients recognized for the
cardiac action. Aconitine has been reported to have a positive
inotropic eﬀect by elevating the intracellular Ca2+ concen-
tration through diﬀerent subcellular mechanisms which lead10 Evidence-Based Complementary and Alternative Medicine
to an increase in Ca2+ transients in myocardial cells [31, 32].
The cardiotonic eﬀect of MHR may be attributed to Ca++
mobilizing property of diterpene alkaloid aconitine.
A signiﬁcant increase in the serum marker enzymes
levels in rats treated with F3 alone shows its cardiotoxic
nature. The ratio of heart weight to body weight also
increased signiﬁcantly with F3 treatment alone depicting the
increase in heart size due to inﬂammation. The reason for
cardiotoxicity of F3 may be aggravation of intracellular Ca2+
occurring due to the presence of high aconitine content. The
HPLC analysis showed that concentration of aconitine was
within acceptable limits in formulations F1 and F2, while it
was much higher in F3 making it toxic.
As mentioned earlier, the preparation of MHR involves
puriﬁcation of aconite roots by treatment with cow urine
in order to convert the poisonous diterpene alkaloid-like
aconitine to othermonoterpene alkaloid-like benzoylaconine
which possesses the same pharmacological activity without
any toxicity [10]. High aconitine content due to improper
puriﬁcation may be one of the reasons for the toxic nature
of formulation F3. The presence of a number of other phyto-
chemicals and heavy metals makes it further complicated
to determine the actual quality of MHR formulation. The
formulationsF1andF2haveproventobesafeindicatingthat
a standard procedure has been followed for the preparation
of these formulations. Thus, stringent regulatory control on
themethodofpreparationofMHRisrequiredtoprovethem
safe for therapeutic use. A schematic representation of the
evaluation performed on the three formulations has been
shown in Figure 7.
Since proprietary Ayurvedic medicines containing
aconite roots are becoming increasingly more popular as a
medicine used in the global market, methods for standard-
ization of those medicines are in demand. The quantitation
results showed that the contents of aconitine were signiﬁ-
cantly varied in the three MHR formulations. So, it is highly
recommended that the determination of aconitum alkaloids
in the proprietary Ayurvedic medicines must be performed
as a routine measurement, so as to provide a safe application
to patients in clinics, and good manufacturing practices.
ToestablishthepotentialofAyurvedicmedicine,research
needs to be conducted on diﬀerent disciplines of Ayurveda
to meet the requirement of the society. This can be done by
standardization of raw materials, methods, and measures for
preparation, preservation, presentation, and administration
of Ayurvedic drugs. Thus, the rationale and judicious use
of modern scientiﬁc methods pertain to the development of
Ayurveda.
5. Conclusion
It is evident from the results that MHR possess signiﬁcant
cardiotonic property. But, the diﬀerences in the results of
toxicological and pharmacological studies prove the need
of stringent regulatory control over the manufacture and
quality control of this ayurvedic formulation. The alternative
medicines in a number of countries have been banned owing
tothetoxicityduetoimproperprocessingofthecomponents
and lack of quality control standards. Thus a need arises for
thedevelopmentofreliablestandardizationtoolsforeﬀective
utility of these traditional medicines.
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